Across TCGA pan-cancer cohorts, IGHM Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated IGHM data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher IGHM Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGHM expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
DLBC, HNSC, and UCEC are the cancer types where IGHM Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.